|

Anti-PD-1 monoclonal antibody Clinical Trials

13 actively recruiting trials across 4 locations

Also known as: Anti-PD-1, Camrelizumab Injection, Opdivo, PD-1 inhibitor, Sintilimab Injection +3 more

Pipeline

Phase 1: 1Phase 2: 3Phase 1/2: 5

Top Sponsors

  • Zhejiang Cancer Hospital1
  • Ze-yang Ding, MD1
  • University of Wisconsin, Madison1
  • Tongji Hospital1
  • LigaChem Biosciences, Inc.1

Indications

  • Cancer13
  • Liver Disease3
  • Liver Cancer3
  • Hepatocellular Carcinoma Non-resectable2
  • Solid Tumor2

Other9 trials

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
N/A
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Phase 2
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Phase 1/2
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Phase 1/2
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Phase 2
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
Phase 2
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
N/A

Birmingham, Alabama1 trial

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

University of Alabama at Birmingham

Phase 1/2

Scottsdale, Arizona1 trial

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

HonorHealth Research Institute

Phase 1/2

Los Angeles, California1 trial

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Cedars Sinai Medical Center

Phase 1/2

Madison, Wisconsin1 trial

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

University of Wisconsin - Madison

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.